Content about Zegerid

October 11, 2011

Sales of antacid tablets are up almost 3%. And while nobody is suggesting that upward trajectory is going to change anytime soon, there will be a decent amount of volatility in the coming year.


Sales of antacid tablets are up almost 3%. And while nobody is suggesting that upward trajectory is going to change anytime soon, there will be a decent amount of volatility in the coming year.


June 20, 2011


Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.



Good things come in three — like the three antacids that for the 52 weeks ended April 17 collectively generated more than $118 million in sales on top of the sales base they had established in the year-ago period.


December 7, 2010

NEW YORK — Last year, the big question on every­one’s mind was: How many brands can actually thrive in what has become a cluttered antacid shelf? Because just exactly how many heartburn sufferers are there?


September 23, 2010

Perrigo has filed for regulatory approval of a generic version of an over-the-counter medication for...

ALLEGAN, Mich. Perrigo has filed for regulatory approval of a generic version of an over-the-counter medication for frequent heartburn, prompting a lawsuit from the branded version’s manufacturer.

The company announced Friday that it had filed for approval for omeprazole and sodium bicarbonate in the 20 mg/1,100 mg strength. The medication is a generic version of Zegerid OTC, made by Schering-Plough HealthCare, a subsidiary of Merck.

 

June 6, 2010

When Schering-Plough Consumer Healthcare began distributing its Zegerid OTC in April, the last piece of...

January 10, 2010

Zegerid OTC was approved for sale as a nonprescription remedy for frequent heartburn last month,...

June 28, 2009

There was speculation in January that Schering-Plough’s switch application around the proton-pump inhibitor Zegerid was...

NEW YORK There was speculation in January that Schering-Plough’s switch application around the proton-pump inhibitor Zegerid was scuttled after receiving a complete response letter from the Food and Drug Administration.